171 related articles for article (PubMed ID: 33805223)
1. QSAR and Pharmacophore Modeling of Nitrogen Heterocycles as Potent Human
Zaki MEA; Al-Hussain SA; Masand VH; Akasapu S; Lewaa I
Molecules; 2021 Mar; 26(7):. PubMed ID: 33805223
[No Abstract] [Full Text] [Related]
2. A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors.
Karki RG; Kulkarni VM
Eur J Med Chem; 2001 Feb; 36(2):147-63. PubMed ID: 11311746
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B.
Masand VH; Al-Hussain SA; Rathore MM; Thakur SD; Akasapu S; Samad A; Al-Mutairi AA; Zaki MEA
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498857
[TBL] [Abstract][Full Text] [Related]
4. Integrated machine learning, molecular docking and 3D-QSAR based approach for identification of potential inhibitors of trypanosomal N-myristoyltransferase.
Singh N; Shah P; Dwivedi H; Mishra S; Tripathi R; Sahasrabuddhe AA; Siddiqi MI
Mol Biosyst; 2016 Nov; 12(12):3711-3723. PubMed ID: 27766319
[TBL] [Abstract][Full Text] [Related]
5. QSAR studies on benzothiophene derivatives as Plasmodium falciparum N-myristoyltransferase inhibitors: Molecular insights into affinity and selectivity.
Garcia ML; de Oliveira AA; Bueno RV; Nogueira VHR; de Souza GE; Guido RVC
Drug Dev Res; 2022 Apr; 83(2):264-284. PubMed ID: 32045013
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors.
Hutton JA; Goncalves V; Brannigan JA; Paape D; Wright MH; Waugh TM; Roberts SM; Bell AS; Wilkinson AJ; Smith DF; Leatherbarrow RJ; Tate EW
J Med Chem; 2014 Oct; 57(20):8664-70. PubMed ID: 25238611
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR of N-myristoyltransferase inhibiting antifungal agents by CoMFA and CoMSIA methods.
Purushottamachar P; Kulkarni VM
Bioorg Med Chem; 2003 Aug; 11(16):3487-97. PubMed ID: 12878142
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic and Predictive QSAR Analysis of Diverse Molecules to Capture Salient and Hidden Pharmacophores for Anti-Thrombotic Activity.
Zaki MEA; Al-Hussain SA; Masand VH; Sabnani MK; Samad A
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361118
[TBL] [Abstract][Full Text] [Related]
10. Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design.
Sheng C; Ji H; Miao Z; Che X; Yao J; Wang W; Dong G; Guo W; Lü J; Zhang W
J Comput Aided Mol Des; 2009 Jun; 23(6):375-89. PubMed ID: 19370313
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors.
Sheng C; Xu H; Wang W; Cao Y; Dong G; Wang S; Che X; Ji H; Miao Z; Yao J; Zhang W
Eur J Med Chem; 2010 Sep; 45(9):3531-40. PubMed ID: 20615585
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
Taha MO; Qandil AM; Al-Haraznah T; Khalaf RA; Zalloum H; Al-Bakri AG
Chem Biol Drug Des; 2011 Sep; 78(3):391-407. PubMed ID: 21679375
[TBL] [Abstract][Full Text] [Related]
13. Cassette dosing approach and quantitative structure-pharmacokinetic relationship study of antifungal N-myristoyltransferase inhibitors.
Hasegawa K; Shindoh H; Shiratori Y; Ohtsuka T; Aoki Y; Ichihara S; Horii I; Shimma N
J Chem Inf Comput Sci; 2002; 42(4):968-75. PubMed ID: 12132899
[TBL] [Abstract][Full Text] [Related]
14. QSAR Study of
Santos-Garcia L; de Mecenas Filho MA; Musilek K; Kuca K; Ramalho TC; da Cunha EFF
Molecules; 2018 Sep; 23(9):. PubMed ID: 30217086
[TBL] [Abstract][Full Text] [Related]
15. Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.
Masand VH; Akasapu S; Gandhi A; Rastija V; Patil MK
Chemometr Intell Lab Syst; 2020 Nov; 206():104172. PubMed ID: 33518858
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the discovery of N-myristoyltransferase inhibitors.
Zhao C; Ma S
ChemMedChem; 2014 Nov; 9(11):2425-37. PubMed ID: 25125080
[TBL] [Abstract][Full Text] [Related]
17. Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1.
French KJ; Zhuang Y; Schrecengost RS; Copper JE; Xia Z; Smith CD
J Pharmacol Exp Ther; 2004 Apr; 309(1):340-7. PubMed ID: 14724220
[TBL] [Abstract][Full Text] [Related]
18. Use of the Monte Carlo Method for OECD Principles-Guided QSAR Modeling of SIRT1 Inhibitors.
Kumar A; Chauhan S
Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 28025857
[TBL] [Abstract][Full Text] [Related]
19. Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites.
Olaleye TO; Brannigan JA; Roberts SM; Leatherbarrow RJ; Wilkinson AJ; Tate EW
Org Biomol Chem; 2014 Nov; 12(41):8132-7. PubMed ID: 25230674
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents.
Das U; Kumar S; Dimmock JR; Sharma RK
Curr Cancer Drug Targets; 2012 Jul; 12(6):667-92. PubMed ID: 22463587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
